| Host: |
HEK293 cells |
| Reactivity: |
Human |
| Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Short Description: |
Recombinant-Human TNFRSF14/HVEM/CD270-C-hFc&His protein was developed from hek293 cells and has a target region of C-hFc&His. For use in research applications. |
| Formulation: |
Lyophilized from a 0.22 Mu m filtered solution of PBS, pH 7.4. Contact us for customized product form or formulation. |
| Immunoreactivity: |
Measured by its binding ability in a functional ELISA. Immobilized Recombinant human HVEM at 5 Mu g/mL (100 Mu L/well) can bind Biotinylated Recombinant human BTLA with a linear range of 1.5-6 Mu g/mL. |
| Gene Symbol: |
TNFRSF14 |
| Gene ID: |
8764 |
| Uniprot ID: |
TNR14_HUMAN |
| Immunogen: |
Recombinant Human TNFRSF14/HVEM/CD270 Protein is produced by HEK293 expression system. The target protein is expressed with sequence (Leu 39-Val 202 ) of human HVEM (Accession #NP_003811.2) fused with an Fc, 6×His tag at the C-terminus. |
| Tissue Specificity | Widely expressed, with the highest expression in lung, spleen and thymus. Expressed in a subpopulation of B cells and monocytes. Expressed in naive T cells. |
| Post Translational Modifications | N-glycosylated. |
| Function | Receptor for four distinct ligands: The TNF superfamily members TNFSF14/LIGHT and homotrimeric LTA/lymphotoxin-alpha and the immunoglobulin superfamily members BTLA and CD160, altogether defining a complex stimulatory and inhibitory signaling network. Signals via the TRAF2-TRAF3 E3 ligase pathway to promote immune cell survival and differentiation. Participates in bidirectional cell-cell contact signaling between antigen presenting cells and lymphocytes. In response to ligation of TNFSF14/LIGHT, delivers costimulatory signals to T cells, promoting cell proliferation and effector functions. Interacts with CD160 on NK cells, enhancing IFNG production and anti-tumor immune response. In the context of bacterial infection, acts as a signaling receptor on epithelial cells for CD160 from intraepithelial lymphocytes, triggering the production of antimicrobial proteins and pro-inflammatory cytokines. Upon binding to CD160 on activated CD4+ T cells, down-regulates CD28 costimulatory signaling, restricting memory and alloantigen-specific immune response. May interact in cis (on the same cell) or in trans (on other cells) with BTLA. In cis interactions, appears to play an immune regulatory role inhibiting in trans interactions in naive T cells to maintain a resting state. In trans interactions, can predominate during adaptive immune response to provide survival signals to effector T cells. (Microbial infection) Acts as a receptor for Herpes simplex virus 1/HHV-1. (Microbial infection) Acts as a receptor for Herpes simplex virus 2/HHV-2. |
| Protein Name | Tumor Necrosis Factor Receptor Superfamily Member 14Herpes Virus Entry Mediator AHerpesvirus Entry Mediator AHveaTumor Necrosis Factor Receptor-Like 2Tr2Cd Antigen Cd270 |
| Database Links | Reactome: R-HSA-388841Reactome: R-HSA-5669034 |
| Cellular Localisation | Cell MembraneSingle-Pass Type I Membrane Protein |
| Alternative Protein Names | Tumor Necrosis Factor Receptor Superfamily Member 14 proteinHerpes Virus Entry Mediator A proteinHerpesvirus Entry Mediator A proteinHvea proteinTumor Necrosis Factor Receptor-Like 2 proteinTr2 proteinCd Antigen Cd270 proteinTNFRSF14 proteinHVEA proteinHVEM proteinUNQ329 proteinPRO509 protein |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
